Product Name :
VY-3-135
Description:
VY-3-135 is a potent ACSS2 inhibitor. VY-3-135 acts as a transition-state mimetic to block ACSS2 activity in vitro and in vivo. Pharmacologic inhibition of ACSS2 as a single agent impaired breast tumor growth. The aqueous solubility of VY-3-135 was 21.7 μM. The aqueous solubility of VY-3-135 was 21.7 μM. VY-3-135 is a potent low nanomolar inhibitor of ACSS2 in cancer cells in vitro. VY-3-135 potently inhibits ACSS2 dependent fatty acid metabolism but has no effect on gene expression in tumors.
CAS:
1824637-41-3
Molecular Weight:
429.51
Formula:
C26H27N3O3
Chemical Name:
(R)-1-Ethyl-2-(hydroxydiphenylmethyl)-N-(2-hydroxypropyl)-1H-benzo[d]imidazole-6-carboxamide
Smiles :
CCN1C(=NC2=CC=C(C=C12)C(=O)NC[C@@H](C)O)C(O)(C1C=CC=CC=1)C1C=CC=CC=1
InChiKey:
KTPYOTKTDCLZHR-GOSISDBHSA-N
InChi :
InChI=1S/C26H27N3O3/c1-3-29-23-16-19(24(31)27-17-18(2)30)14-15-22(23)28-25(29)26(32,20-10-6-4-7-11-20)21-12-8-5-9-13-21/h4-16,18,30,32H,3,17H2,1-2H3,(H,27,31)/t18-/m1/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Cryptotanshinone} medchemexpress|{Cryptotanshinone} Autophagy|{Cryptotanshinone} Purity & Documentation|{Cryptotanshinone} Formula|{Cryptotanshinone} supplier|{Cryptotanshinone} Epigenetic Reader Domain}
Shelf Life:
≥12 months if stored properly.{{Fosaprepitant dimeglumine} web|{Fosaprepitant dimeglumine} Neurokinin Receptor|{Fosaprepitant dimeglumine} Protocol|{Fosaprepitant dimeglumine} Description|{Fosaprepitant dimeglumine} custom synthesis|{Fosaprepitant dimeglumine} Autophagy}
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:23775868
Additional information:
VY-3-135 is a potent ACSS2 inhibitor. VY-3-135 acts as a transition-state mimetic to block ACSS2 activity in vitro and in vivo. Pharmacologic inhibition of ACSS2 as a single agent impaired breast tumor growth. The aqueous solubility of VY-3-135 was 21.7 μM. The aqueous solubility of VY-3-135 was 21.7 μM. VY-3-135 is a potent low nanomolar inhibitor of ACSS2 in cancer cells in vitro. VY-3-135 potently inhibits ACSS2 dependent fatty acid metabolism but has no effect on gene expression in tumors.|Product information|CAS Number: 1824637-41-3|Molecular Weight: 429.51|Formula: C26H27N3O3|Chemical Name: (R)-1-Ethyl-2-(hydroxydiphenylmethyl)-N-(2-hydroxypropyl)-1H-benzo[d]imidazole-6-carboxamide|Smiles: CCN1C(=NC2=CC=C(C=C12)C(=O)NC[C@@H](C)O)C(O)(C1C=CC=CC=1)C1C=CC=CC=1|InChiKey: KTPYOTKTDCLZHR-GOSISDBHSA-N|InChi: InChI=1S/C26H27N3O3/c1-3-29-23-16-19(24(31)27-17-18(2)30)14-15-22(23)28-25(29)26(32,20-10-6-4-7-11-20)21-12-8-5-9-13-21/h4-16,18,30,32H,3,17H2,1-2H3,(H,27,31)/t18-/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: To be determined|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|References:|Miller KD, Pniewski K, Perry CE, Papp SB, Shaffer JD, Velasco-Silva JN, Casciano JC, Aramburu TM, Srikanth YVV, Cassel J, Skordalakes E, Kossenkov AV, Salvino JM, Schug ZT. Targeting ACSS2 with a Transition-State Mimetic Inhibits Triple-Negative Breast Cancer Growth. Cancer Res. 2021 Mar 1;81(5):1252-1264. doi: 10.1158/0008-5472.CAN-20-1847. Epub 2021 Jan 7. PMID: 33414169; PMCID: PMC8026699.Products are for research use only. Not for human use.|
